Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Rhumbline Advisers

Rhumbline Advisers increased its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 20.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,638 shares of the company’s stock after acquiring an additional 7,111 shares during the period. Rhumbline Advisers owned approximately 0.12% of Keros Therapeutics worth $1,903,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of KROS. ADAR1 Capital Management LLC acquired a new stake in shares of Keros Therapeutics in the 4th quarter worth approximately $27,367,000. Redmile Group LLC acquired a new stake in shares of Keros Therapeutics in the 1st quarter worth approximately $36,576,000. Darwin Global Management Ltd. grew its holdings in shares of Keros Therapeutics by 35.4% in the 1st quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock worth $95,060,000 after acquiring an additional 375,523 shares during the period. Franklin Resources Inc. grew its holdings in shares of Keros Therapeutics by 47.9% in the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after acquiring an additional 226,674 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after acquiring an additional 176,803 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Trading Down 2.7 %

Shares of KROS opened at $55.80 on Friday. The firm has a market capitalization of $2.01 billion, a P/E ratio of -10.83 and a beta of 1.22. The stock’s fifty day simple moving average is $49.53 and its 200 day simple moving average is $53.16. Keros Therapeutics, Inc. has a twelve month low of $27.02 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The company had revenue of $0.04 million during the quarter. During the same period in the prior year, the company posted ($1.27) EPS. Sell-side analysts predict that Keros Therapeutics, Inc. will post -4.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on KROS shares. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Truist Financial reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Oppenheimer started coverage on Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price on the stock. Finally, Bank of America lowered their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $89.86.

Insider Activity at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.90% of the stock is owned by insiders.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.